文献速递肝病

低剂量糖皮质激素与自身免疫性肝炎的不良事件

Adverse events related to low dose corticosteroids in autoimmune hepatitis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-15

该回顾性队列纳入476例自身免疫性肝炎患者,中位随访13年,分析当前激素用量与白内障、糖尿病和骨折的关系。低剂量泼尼松(龙)增加骨折风险,较高剂量增加白内障和糖尿病风险,布地奈德增加白内障和骨折风险,提示低剂量亦不能避免不良事件。

要点

  • 低剂量泼尼松(龙)(0.1-5.0 mg/d)增加骨折风险
  • 较高剂量泼尼松(龙)(>5.0 mg/d)增加白内障和糖尿病风险
  • 布地奈德增加白内障和骨折风险,且不依赖既往泼尼松(龙)使用

核心结论

  • 即使低剂量糖皮质激素也常导致显著不良事件,低剂量并不能避免不良事件。

研究设计与样本

  • 回顾性收集476例确诊自身免疫性肝炎患者(77%女性)的数据。
  • 采用二元logistic回归与广义估计方程分析当前激素使用与诊断后新发白内障、糖尿病和骨折的关联。
  • 校正性别、年龄、诊断时肝硬化和既往3年泼尼松(龙)使用。
  • 共记录6634患者年,中位每例13年(范围1-40),诊断时中位年龄44岁(范围2-88)。

主要发现

  • 120例(25%)患者记录到不良事件。
  • 低剂量泼尼松(龙)(0.1-5.0 mg/d)增加骨折的比值比。
  • 较高剂量泼尼松(龙)(>5.0 mg/d)增加白内障和糖尿病的比值比。
  • 布地奈德增加白内障和骨折的比值比,且独立于既往1、2或3年泼尼松(龙)使用。

关键数值与推荐

  • 低剂量泼尼松(龙)定义为0.1-5.0 mg/d,较高剂量定义为>5.0 mg/d。

临床怎么用

  • 对长期维持治疗的自身免疫性肝炎患者,即使使用低剂量激素也应监测骨折、白内障和糖尿病。
  • 使用布地奈德时需关注白内障和骨折风险,不应因既往未用泼尼松(龙)而忽视。

局限性

  • 回顾性设计可能低估或错分不良事件。
  • 研究人群来自特定中心,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoimmune hepatitis requires long-term therapy, and systemic corticosteroids are the backbone of therapeutic management. Prolonged use of corticosteroids may lead to adverse events but data from long-term studies are mainly derived from studies in rheumatic diseases. AIM: To assess cataract, diabetes and fractures in relation to corticosteroid doses in the long-term maintenance treatment of patients with autoimmune hepatitis. METHODS: We retrospectively collected data on 476 patients (77% women) with an established diagnosis of autoimmune hepatitis. Binary logistic regression with a generalised estimating equation was used to analyse the association between current corticosteroid use and the incidence of cataract, diabetes and fractures with onset after autoimmune hepatitis diagnosis. We corrected for sex, age, cirrhosis at diagnosis and predniso(lo)ne use in the prior 3 years to account for possible ongoing effects. RESULTS: A total of 6634 years, with a median of 13 (range 1-40) per patient were recorded. The median age at diagnosis was 44 years (range 2-88). Adverse events were documented in 120 (25%) patients. Low-dose predniso(lo)ne (0.1-5.0 mg/d) increased the odds of fractures whereas higher doses (>5.0 mg/d) increased the odds of cataracts and diabetes. Budesonide increased the odds of cataract and fractures; this effect was independent of predniso(lo)ne use in the prior 1, 2 or 3 years. CONCLUSIONS: Even low doses of corticosteroids frequently lead to substantial adverse events refuting the assumption that adverse events are prevented by administering low doses.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. van den Brand FF, van der Veen KS, Lissenberg-Witte BI, et al. Adverse events related to low dose corticosteroids in autoimmune hepatitis. Aliment Pharmacol Ther. 2019. PMID: 31617229. doi:10.1111/apt.15528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。